The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021
Journal of Antimicrobial Chemotherapy · 01.03.2024 · 79 (3) · 526-530
DOI: 10.1093/jac/dkad370 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 01.02.2024. Verfasst von Min Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Clinical Research Center for Infectious Disease (HIV/AIDS), Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. Hauptthemen laut MEDLINE: HIV-1, HIV Seropositivity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Science and Technology Committee.
Abstract (Originalsprache)
Background
HIV-1 drug resistance is a huge challenge in the era of ART.
Objectives
To investigate the prevalence and characteristics of acquired HIV-1 drug resistance (ADR) in Shanghai, China.
Methods
An epidemiological study was performed among people living with human immunodeficiency virus (PLWH) receiving ART in Shanghai from January 2017 to December 2021. A total of 8669 PLWH were tested for drug resistance by genotypic resistance testing. Drug resistance mutations (DRMs) were identified using the Stanford University HIV Drug Resistance Database program.
Results
Ten HIV-1 subtypes/circulating recombinant forms (CRFs) were identified, mainly including CRF01_AE (46.8%), CRF07_BC (35.7%), B (6.4%), CRF55_01B (2.8%) and CRF08_BC (2.4%). The prevalence of ADR was 48% (389/811). Three NRTI-associated mutations (M184V/I/L, S68G/N/R and K65R/N) and four NNRTI-associated mutations (V179D/E/T/L, K103N/R/S/T, V106M/I/A and G190A/S/T/C/D/E/Q) were the most common DRMs. These DRMs caused high-level resistance to lamivudine, emtricitabine, efavirenz and nevirapine. The DRM profiles appeared to be significantly different among different subtypes.
Conclusions
We revealed HIV-1 subtype characteristics and the DRM profile in Shanghai, which provide crucial guidance for clinical treatment and management of PLWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Clinical Research Center for Infectious Disease (HIV/AIDS), Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
- National Clinical Research Center for Infectious Disease, The Third People's Hospital of Shenzhen, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen 518112, Guangdong, China.
ORCID-Profile: Hongzhou Lu
Förderung
- National Natural Science Foundation of China
- Shanghai Science and Technology Committee
Zitieren
APA
Zhang, M., Ma, Y., Wang, G., Wang, Z., Wang, Q., Li, X., Lin, F., Qiu, J., Chen, D., Shen, Y., Zhang, C., & Lu, H. (2024). The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021. Journal of Antimicrobial Chemotherapy, 79(3), 526-530. https://doi.org/10.1093/jac/dkad370
Vancouver
Zhang M, Ma Y, Wang G, Wang Z, Wang Q, Li X, et al. The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021. Journal of Antimicrobial Chemotherapy. 2024;79(3):526-530. doi:10.1093/jac/dkad370
BibTeX
@article{Zhang2024,
author = {Zhang, Min and Ma, Yingying and Wang, Gang and Wang, Zhenyan and Wang, Qianying and Li, Xin and Lin, Feng and Qiu, Jianping and Chen, Daihong and Shen, Yinzhong and Zhang, Chiyu and Lu, Hongzhou},
title = {The profile of HIV-1 drug resistance in Shanghai, China: a retrospective study from 2017 to 2021},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
volume = {79},
number = {3},
pages = {526--530},
doi = {10.1093/jac/dkad370}
}
EUVIMED